This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Alberta directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $191,250
SECRET: Study of rivaroxaban for CeREbral venous Thrombosis
CIHR · 2017 · Co-investigator
- $450,288
Direct Acting Oral Anticoagulants in Acute Ischemic Stroke.
CIHR · 2014 · Principal investigator
- $1,204,705
PURE-MIND: A Population-based Study of Covert Cerebrovascular Disease and Its Contribution to Age-Related Cognitive Decline
CIHR · 2013 · Co-investigator
SECRET: Study of rivaroxaban for CeREbral venous Thrombosis
Principal investigators: Field, Thalia S
Keywords: Anticoagulation; Cerebral Venous Thrombosis; Cognition; Health Economics; Patient-Centered Outcomes; Prognosis; Rare Diseases
Direct Acting Oral Anticoagulants in Acute Ischemic Stroke.
Principal investigators: Butcher, Kenneth S; Benavente, Oscar; Hart, Robert G; Sharma, Mukul M
Keywords: Blood Pressure; Intracerebral Hemorrhage
PURE-MIND: A Population-based Study of Covert Cerebrovascular Disease and Its Contribution to Age-Related Cognitive Decline
Principal investigators: Smith, Eric E
Keywords: Aging; Cerebrovascular Disease; Cognitive Impairment; Dementia; Mri; Stroke
Effect of blood pressure variability on severity of cerebral small vessel disease and cognition in the SPS3 Study
Principal investigators: Field, Thalia S
Keywords: Cognition/Dementia; Epidemiology; Neuroimaging; Stroke/Cerebrovascular Disease
Standards for determining the vascular contribution to neurodegeneration.
Principal investigators: Smith, Eric E
Keywords: Alzheimers
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.